These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 30055128)

  • 1. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
    Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
    Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
    Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
    Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
    Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
    Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's Disease Associated with G2019S LRRK2 Mutations without Lewy Body Pathology.
    Jackson LM; Woodruff BK; Tremblay C; Shill HA; Beach TG; Serrano GE; Adler CH
    Mov Disord Clin Pract; 2024 Jul; 11(7):874-878. PubMed ID: 38757351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2
    Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
    J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
    Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
    Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
    Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
    Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
    Ito G; Utsunomiya-Tate N
    Biomolecules; 2023 May; 13(5):. PubMed ID: 37238714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
    Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
    J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
    Ho DH; Seol W; Son I
    Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.
    Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R
    Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions.
    Thomas JM; Wang X; Guo G; Li T; Dai B; Nucifora LG; Nucifora FC; Liu Z; Xue F; Liu C; Ross CA; Smith WW
    J Cell Physiol; 2020 Oct; 235(10):7309-7320. PubMed ID: 32180220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
    Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
    Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
    Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
    Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
    Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
    Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
    Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
    Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase.
    Ho DH; Kim H; Nam D; Sim H; Kim J; Kim HG; Son I; Seol W
    Cell Biochem Funct; 2018 Dec; 36(8):431-442. PubMed ID: 30411383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.